CG Therapeutics, Inc. is a Seattle biotechnology company founded in 2005 to develop new immunotherapeutics that neutralize hCG, a powerful hormone that promotes both pregnancy and cancer.

CGT's lead product, CG201, is an injection that stimulates a person’s immune system to produce antibodies with anti-tumor effects. CG201's anti-hCG antibodies also can prevent pregnancy.

CG201 benefits from twenty years of previous development by government, university, and corporate teams. Prior formulations of CG201 have been found safe and effective for pregnancy prevention and cancer therapy in multiple human clinical trials. CG201 is now being readied to enter advanced clinical testing in both applications.